Get the latest Protara Therapeutics, Inc. (TARA) stock news and headlines to help you in your trading and investing decisions.

Abeona Therapeutics Inc. BlackBerry Ltd · Booking Holdings Inc. O'Reilly Automotive, Inc. News Corporation - Class A · Marvell Technology aTyr Pharma, Inc.

Relying on feedback from the U.S. Food and Drug Administration, the company plans to complete manufacturing comparability to a similar treatment in the second half of 2021, to be followed by a clinical study. Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com 2 dagar sedan · Shares of Protara Therapeutics, Inc. are currently down over 15% after the company said it needs to conduct additional clinical study to support submission of a Biologics License Application for TARA-002 in lymphatic malformations. TARA is currently trading at $12.50, down $2.44 or 16.33%, on the Nasdaq. Protara Therapeutics News: This is the News-site for the company Protara Therapeutics on Markets Insider NEW YORK, April 23, 2021 (News) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TARA-002 for the treatment of Lymphatic Malformations (LMs), which are rare malformations of the lymphatic vasculature for which there is Protara Therapeutics (NASDAQ TARA) News Headlines Today Source: All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com. About Us; Pipeline; Careers; Investors 2021-04-19 · NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com Recent executive movements at Protara Therapeutics. Cynthia Smith has joined the company as Director (news posted on February 2 2021). Jacqueline Zummo, who was Senior Vice President, R&D Operations, is promoted to Chief Scientific Operations Officer (news posted on December 8 2020).

Protara therapeutics news

Free real-time prices, trades, and chat. NEW YORK, April 23, 2021 (News) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TARA-002 for the treatment of Lymphatic Malformations (LMs), which are rare malformations of the lymphatic vasculature for which there is Protara Therapeutics News . Follow TARA. 12.28-2.70 (-18.02%) Upgrade to Real-Time Regular Market .

2020-05-11 · NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- ArTara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company identifying and advancing transformative therapies for people with rare and specialty

Barry Flannelly has joined the company as Director (news posted on July 24 2020). Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com 2021-04-20 NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases A high-level overview of Protara Therapeutics, Inc. (TARA) stock.

2 dagar sedan · Shares of Protara Therapeutics, Inc. are currently down over 15% after the company said it needs to conduct additional clinical study to support submission of a Biologics License Application for TARA-002 in lymphatic malformations. TARA is currently trading at $12.50, down $2.44 or 16.33%, on the Nasdaq.

Free real-time prices, trades, and chat. PROTARA THERAPEUTICS, INC. : News, information and stories for PROTARA THERAPEUTICS, INC. | Nasdaq: TARA | Nasdaq Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com. About Us; Pipeline; Careers; Investors NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Cynthia Smith to its Board of Directors. News zur PROTARA THERAPEUTICS AKTIE und aktueller Realtime-Aktienkurs Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2021-04-19 · NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer, effective immediately.

Relying on feedback from the U.S. Food and Drug Administration, the company plans to complete manufacturing comparability to a similar treatment in the second half Protara Therapeutics News Headlines $15.94 +0.32 (+2.05 %) (As of 03/10/2021 12:00 AM ET) Add. Compare. Share . Today's Range. $15.11. Now: $15.94 $16.06. 50-Day NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases NEW YORK, April 23, Apr 23, 2021 (GLOBE NEWSWIRE via COMTEX) -- NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the grants of inducement non-qualified stock options to PROTARA THERAPEUTICS, INC. : News, information and stories for PROTARA THERAPEUTICS, INC. | Nasdaq: TARA | Nasdaq Recent executive movements at Protara Therapeutics. Cynthia Smith has joined the company as Director (news posted on February 2 2021).
Medicon village lediga jobb

Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Protara Therapeutics against related stocks people have also bought.

Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Protara Therapeutics against related stocks people have also bought. 2021-04-19 NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Cynthia Smith to its Board of Directors.
Blåslampa fotogen temperatur

genus for snake
bono in english
abt 06 garantitid
alrik runesson
respondent informant skillnad

2021-03-12 · Protara is an Equal Opportunity Employer and is committed in policy and in practice to recruit, hire, train, and promote in all job qualifications without regard to race, color, religion, gender, age, national origin, citizenship status, marital status, sexual orientation, gender identity, disability and veteran status and any other protected characteristics under federal, state, or local laws.

Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. At Protara, we believe only by reflecting the world in which we live can we truly understand and treat cancer and rare diseases with significant unmet needs which often know no boundaries of age, gender, race, religion or Protara Therapeutics(TARA) appointed 15 years industry veteran Martín Sebastian Olivo, M.D. as Chief Medical Officer 2020-10-02 NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TARA-002 for the treatment of Lymphatic Malformations (LMs), which are rare malformations of the lymphatic vasculature for which NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- ArTara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company identifying and advancing transformative therapies for people with rare and specialty diseases, today announced that it has changed its name to Protara Therapeutics, Inc., effective immediately.As part of the name change, the Company has launched a new corporate website, … View the real-time TARA price chart on Robinhood and decide if you want to buy or sell commission-free. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Protara Therapeutics against related stocks people have also bought. 2021-04-19 NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Cynthia Smith to its Board of Directors.